Does ARS Pharmaceuticals Inc (SPRY) offer a good opportunity for investors?

With 1.42 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.34 million shares. The 52-week range on SPRY shows that it touched its highest point at $18.51 and its lowest point at $7.55 during that stretch. It currently has a 1-year price target of $32.00. Beta for the stock currently stands at 0.99.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SPRY was up-trending over the past week, with a rise of 3.53%, but this was down by -14.90% over a month. Three-month performance dropped to -20.28% while six-month performance fell -9.05%. The stock gained 22.18% in the past year, while it has gained 2.84% so far this year. A look at the trailing 12-month EPS for SPRY yields -0.51 with Next year EPS estimates of -0.54. For the next quarter, that number is -0.24. This implies an EPS growth rate of -15.44% for this year and 18.44% for next year. EPS is expected to grow by 48.88% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -1.44%.

Float and Shares Shorts:

At present, 97.15 million SPRY shares are outstanding with a float of 51.30 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SPRY since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.18152 being high and -$0.86221 being low. For SPRY, this leads to a yearly average estimate of -$0.658. Based on analyst estimates, the high estimate for the next quarter is -$0.12 and the low estimate is -$0.25. The average estimate for the next quarter is thus -$0.19.